Mansi Goyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mansi Goyal has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Abigail Hockett
Department of Genetics and Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
1 shared publicationAmira Ali
Department of Genetics and Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
1 shared publicationAndrew L. Chin
McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA
1 shared publication- Anh N. Luu
Computational Medicine Program, The University of North Carolina at Chapel Hill , Chapel Hill, NC 27599
1 shared publication - Aryan Dalal
Department of Genetics and Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
1 shared publication - Brett R. Chrest
Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaeb2695
The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart
Trametinib (Trm) is a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor that potently and persistently abrogates extracellular signal–regulated kinase 1/2 activation. Trm initially was used to treat BRAF Val 600 →Glu (V600E)-mutated melanoma, but its Food and Drug Administration–approved indications are expanding rapidly. Trm generally is well tolerated, but it can cause dose-limiting cardiomyopathy and heart failure. Here, we characterize a mouse model of Trm cardiotoxicity using complementary in vitro approaches to show that Trm induces mitochondrial dysfunction in cardiomyocytes and some cancer cell types. In vivo, Trm caused contractile dysfunction within 3 days and heart failure within 2 weeks. High-resolution respirometry using isolated cardiac mitochondria revealed that Trm compromises oxidative metabolism, in part, through blunted activity of electron transport system complexes. Trm-mediated mitochondrial injury led to the release of mitochondrial damage–associated molecular patterns including mitochondrial DNA in both mice and humans, triggering activation of canonical innate immune pathways including cGAS-STING. In multiple rodent and human cardiomyocyte platforms, Trm diminished mitochondrial respiratory capacity at nanomolar concentrations, but this lesion was reversed by expression of a phosphomimetic signal transducer and activator of transcription 3–S727 construct. We also found that Trm induced mitochondrial dysfunction in some but not all cancer cell lines, identifying a previously unrecognized effect that could contribute to Trm’s anticancer efficacy.
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaeb2695
Open AccessThe MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart
Trametinib (Trm) is a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor that potently and persistently abrogates extracellular signal–regulated kinase 1/2 activation. Trm initially was used to treat BRAF Val 600 →Glu (V600E)-mutated melanoma, but its Food and Drug Administration–approved indications are expanding rapidly. Trm generally is well tolerated, but it can cause dose-limiting cardiomyopathy and heart failure. Here, we characterize a mouse model of Trm cardiotoxicity using complementary in vitro approaches to show that Trm induces mitochondrial dysfunction in cardiomyocytes and some cancer cell types. In vivo, Trm caused contractile dysfunction within 3 days and heart failure within 2 weeks. High-resolution respirometry using isolated cardiac mitochondria revealed that Trm compromises oxidative metabolism, in part, through blunted activity of electron transport system complexes. Trm-mediated mitochondrial injury led to the release of mitochondrial damage–associated molecular patterns including mitochondrial DNA in both mice and humans, triggering activation of canonical innate immune pathways including cGAS-STING. In multiple rodent and human cardiomyocyte platforms, Trm diminished mitochondrial respiratory capacity at nanomolar concentrations, but this lesion was reversed by expression of a phosphomimetic signal transducer and activator of transcription 3–S727 construct. We also found that Trm induced mitochondrial dysfunction in some but not all cancer cell lines, identifying a previously unrecognized effect that could contribute to Trm’s anticancer efficacy.
- 30 January 2026
- Published by Oxford University Press (OUP) in Genetics
- Vol. 233 (1)
Genetic determinants of heart failure susceptibility and response in the collaborative cross mouse population
Genetic variation and lived experiences shape how our hearts respond to chronic stress and development of heart failure, manifested as compromised pumping function and abnormal hemodynamics. The hallmark of heart failure etiology is excessive stress signals followed by maladaptive structural, electrical, and functional changes to the heart muscle, also known as cardiac remodeling. The specific genetic mechanisms which underly such phenomenon, however, are still unclear, due in part to difficulties in accounting for environmental effects in human population studies. To overcome this challenge, we used the Collaborative Cross (CC) mouse population to investigate heritable susceptibility to cardiovascular stress through chronic β-adrenergic receptor stimulation with the β-agonist isoproterenol (ISO), which targets the common signaling gateway to heart failure, regardless of the particular upstream stressor. Across 8 founder and 63 CC lines, we measured nonfailing and failing heart characteristics represented by cardiac structure and function, organ weights, and cell morphology. Genome-wide QTL mapping detected 49 genome-wide significant loci, collapsing to 20 unique intervals (9 significant for multiple traits and 11 trait-specific), averaging 12.83 Mb in size. To identify high-confidence candidate genes from these loci, we augmented our trait mapping with coding variants drawn from sequencing data, tractability in an in vitro rat cardiomyocyte model, and previously reported protein functions and/or mouse or human phenotypes. This approach recovered both known regulators, such as Hey2, and new candidates. Functional tests in in vitro models highlight 3 candidate genes that modulate hypertrophic growth: Abcb10, Mrps5, and Lmod3. Abcb10 knockdown increased cell size at baseline and further with ISO, consistent with loss of a mitochondrial stress-buffering role. Mrps5 knockdown blunted stress-induced hypertrophy, possibly related to its previously known involvement in oxidative stress regulation. Lmod3 knockdown also attenuated hypertrophy, potentially via actin-assembly control under adrenergic stress. Together, these results reveal heritable pathways of β-adrenergic remodeling in mice and provide an interpretable, translational, and stepwise framework to prioritize candidate genes within broad loci for mechanistic studies of heart failure.
- 30 January 2026
- Published by Oxford University Press (OUP) in Genetics
- Vol. 233 (1)
Genetic determinants of heart failure susceptibility and response in the collaborative cross mouse population
Genetic variation and lived experiences shape how our hearts respond to chronic stress and development of heart failure, manifested as compromised pumping function and abnormal hemodynamics. The hallmark of heart failure etiology is excessive stress signals followed by maladaptive structural, electrical, and functional changes to the heart muscle, also known as cardiac remodeling. The specific genetic mechanisms which underly such phenomenon, however, are still unclear, due in part to difficulties in accounting for environmental effects in human population studies. To overcome this challenge, we used the Collaborative Cross (CC) mouse population to investigate heritable susceptibility to cardiovascular stress through chronic β-adrenergic receptor stimulation with the β-agonist isoproterenol (ISO), which targets the common signaling gateway to heart failure, regardless of the particular upstream stressor. Across 8 founder and 63 CC lines, we measured nonfailing and failing heart characteristics represented by cardiac structure and function, organ weights, and cell morphology. Genome-wide QTL mapping detected 49 genome-wide significant loci, collapsing to 20 unique intervals (9 significant for multiple traits and 11 trait-specific), averaging 12.83 Mb in size. To identify high-confidence candidate genes from these loci, we augmented our trait mapping with coding variants drawn from sequencing data, tractability in an in vitro rat cardiomyocyte model, and previously reported protein functions and/or mouse or human phenotypes. This approach recovered both known regulators, such as Hey2, and new candidates. Functional tests in in vitro models highlight 3 candidate genes that modulate hypertrophic growth: Abcb10, Mrps5, and Lmod3. Abcb10 knockdown increased cell size at baseline and further with ISO, consistent with loss of a mitochondrial stress-buffering role. Mrps5 knockdown blunted stress-induced hypertrophy, possibly related to its previously known involvement in oxidative stress regulation. Lmod3 knockdown also attenuated hypertrophy, potentially via actin-assembly control under adrenergic stress. Together, these results reveal heritable pathways of β-adrenergic remodeling in mice and provide an interpretable, translational, and stepwise framework to prioritize candidate genes within broad loci for mechanistic studies of heart failure.